Instrument Inactif

Communiqués Oxford Immunotec Global PLC

Actions

OXFD

GB00BGFBB958

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea	08/02/21	GL
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses	04/02/21	GL
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19	14/01/21	GL
OXFORD IMMUNOTEC INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD	14/01/21	BU
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study	13/01/21	GL
Oxford Immunotec Announces the Foundation of the Global T Cell Expert Consortium, Whose First Meeting Took Place This Week	16/12/20	GL
Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit, Used to Automate the T-SPOT®.TB Test Workflow, for IVD Use in South Korea	10/12/20	GL
Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020	23/11/20	GL
Data Showing SARS-CoV-2 Reactive T Cells are Associated with Protection from COVID-19 – and Can Be Both Detected and Measured Using Oxford Immunotec’s T-SPOT® Technology – is Published by Public Health England and Oxford Immunotec	10/11/20	GL
Oxford Immunotec Files Submission to Food and Drug Administration (FDA) for the T-Cell Select™ Reagent Kit	05/11/20	GL
Oxford Immunotec Reports Third Quarter 2020 Financial Results	03/11/20	GL
UK Vaccines Taskforce has Selected Oxford Immunotec as the Sole Supplier of T cell Testing for SARS-CoV-2 Specific Responses in New COVID Vaccine Trials	22/10/20	GL
Oxford Immunotec Schedules Third Quarter 2020 Earnings Release and Conference Call for November 3, 2020	21/10/20	GL
Oxford Immunotec Announces Food and Drug Administration (FDA) Clearance of the T-SPOT®.TB Test for Use in Pediatrics Over the Age of Two	29/09/20	GL
Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® Discovery™ SARS-CoV-2 Test	22/09/20	GL
Oxford Immunotec Global : Second Quarter 2020 EarningsPresentation	04/08/20	PU
Oxford Immunotec Reports Second Quarter 2020 Financial Results	04/08/20	GL
Oxford Immunotec Schedules Second Quarter 2020 Earnings Release and Conference Call for August 4, 2020	21/07/20	GL
Oxford Immunotec Announces Agreement with Stop TB Partnership - Global Drug Facility (GDF) to Provide Access to the T-SPOT®.TB Test for 100+ TB Burden Countries	20/07/20	GL
Oxford Immunotec Reports First Quarter 2020 Financial Results	05/05/20	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Oxford Immunotec Global PLC

Actions

OXFD

GB00BGFBB958

Communiqués

Filtres